Will your breakfast ruin this cancer pill? new trial investigates

NCT ID NCT07550946

Not yet recruiting Knowledge-focused Sponsor: Voronoi, Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial in 24 healthy adults examines how food and a common stomach-acid reducer (a proton pump inhibitor) change the way the body absorbs a new drug called VRN101099, which is being developed for solid tumors. Researchers will measure drug levels in the blood and urine under different conditions to find the best way to take it. The goal is to guide future dosing instructions for cancer patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VRN101099
What this could lead to: If successful, this study will help determine the best way to take VRN101099 with or without food or acid reducers, potentially improving future cancer treatments.
What could go wrong: This is an early phase 1 trial in only 24 healthy people, not patients. Results may not predict effects in cancer patients or guarantee safety or effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY ADULT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY ADULT

Contacts and locations

Locations

Nucleus Network

Melbourne, Victoria, 3004, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.